JP2015524427A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524427A5 JP2015524427A5 JP2015524182A JP2015524182A JP2015524427A5 JP 2015524427 A5 JP2015524427 A5 JP 2015524427A5 JP 2015524182 A JP2015524182 A JP 2015524182A JP 2015524182 A JP2015524182 A JP 2015524182A JP 2015524427 A5 JP2015524427 A5 JP 2015524427A5
- Authority
- JP
- Japan
- Prior art keywords
- oxyntomodulin derivative
- seq
- fatty liver
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims description 29
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 208000010706 fatty liver disease Diseases 0.000 claims 9
- 229920000642 polymer Polymers 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102400000319 Oxyntomodulin Human genes 0.000 claims 1
- 101800001388 Oxyntomodulin Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 235000009200 high fat diet Nutrition 0.000 description 19
- 241000699800 Cricetinae Species 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 5
- 108010019598 Liraglutide Proteins 0.000 description 5
- 229940007428 victoza Drugs 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0081475 | 2012-07-25 | ||
| KR1020120081475A KR101968344B1 (ko) | 2012-07-25 | 2012-07-25 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| PCT/KR2013/006668 WO2014017843A1 (en) | 2012-07-25 | 2013-07-25 | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018007302A Division JP6499333B2 (ja) | 2012-07-25 | 2018-01-19 | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524427A JP2015524427A (ja) | 2015-08-24 |
| JP2015524427A5 true JP2015524427A5 (enExample) | 2017-03-09 |
Family
ID=49997578
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524182A Pending JP2015524427A (ja) | 2012-07-25 | 2013-07-25 | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 |
| JP2018007302A Active JP6499333B2 (ja) | 2012-07-25 | 2018-01-19 | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 |
| JP2019046854A Active JP6903086B2 (ja) | 2012-07-25 | 2019-03-14 | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 |
| JP2021063405A Withdrawn JP2021107403A (ja) | 2012-07-25 | 2021-04-02 | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018007302A Active JP6499333B2 (ja) | 2012-07-25 | 2018-01-19 | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 |
| JP2019046854A Active JP6903086B2 (ja) | 2012-07-25 | 2019-03-14 | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 |
| JP2021063405A Withdrawn JP2021107403A (ja) | 2012-07-25 | 2021-04-02 | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20150182593A1 (enExample) |
| EP (3) | EP2884994B1 (enExample) |
| JP (4) | JP2015524427A (enExample) |
| KR (1) | KR101968344B1 (enExample) |
| CN (2) | CN104507492B (enExample) |
| AR (1) | AR091903A1 (enExample) |
| AU (2) | AU2013293714B2 (enExample) |
| BR (2) | BR122022025353B1 (enExample) |
| CA (2) | CA2888407C (enExample) |
| CL (4) | CL2015000177A1 (enExample) |
| DK (1) | DK3384925T3 (enExample) |
| ES (2) | ES2942187T3 (enExample) |
| IL (2) | IL236913B (enExample) |
| MX (2) | MX360024B (enExample) |
| MY (2) | MY171493A (enExample) |
| NZ (2) | NZ731657A (enExample) |
| PE (1) | PE20150633A1 (enExample) |
| PH (2) | PH12015500158B1 (enExample) |
| RU (2) | RU2768853C1 (enExample) |
| SG (2) | SG11201500519UA (enExample) |
| TW (3) | TWI661837B (enExample) |
| UA (2) | UA118177C2 (enExample) |
| WO (1) | WO2014017843A1 (enExample) |
| ZA (2) | ZA201501238B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11197914B2 (en) | 2016-04-22 | 2021-12-14 | Shenzhen Turier Biotech Co. Ltd. | GLP-1R/GCGR dual target agonist polypeptide for treatment of fatty liver diseases, hyperlipemia and arteriosclerosis |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2739209C2 (ru) | 2011-06-10 | 2020-12-21 | Ханми Сайенс Ко., Лтд. | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения |
| SI2721062T1 (sl) | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| AR098616A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| MX369656B (es) | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
| DK3127923T3 (da) * | 2014-03-31 | 2021-11-22 | Hanmi Pharm Ind Co Ltd | Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) * | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) * | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| AR103322A1 (es) | 2014-12-30 | 2017-05-03 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón con estabilidad mejorada |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| CR20180034A (es) * | 2015-06-30 | 2018-04-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo. |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| AU2016382394B2 (en) * | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
| AR107823A1 (es) * | 2016-03-07 | 2018-06-06 | Hanmi Pharm Ind Co Ltd | Derivados de polietilenglicol y uso de los mismos |
| EA201891946A1 (ru) * | 2016-03-10 | 2019-04-30 | Медиммун Лимитед | Коагонисты глюкагона и glp-1 для лечения ожирения |
| PE20190355A1 (es) * | 2016-06-29 | 2019-03-07 | Hanmi Pharm Ind Co Ltd | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo |
| AU2017332408B2 (en) | 2016-09-23 | 2022-02-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| WO2018069422A1 (en) * | 2016-10-12 | 2018-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of non-alcoholic fatty liver disease |
| CN110545852B (zh) | 2017-02-07 | 2023-05-26 | 韩美药品株式会社 | 非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法 |
| AU2018239037B2 (en) | 2017-03-23 | 2022-05-26 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| KR102686854B1 (ko) * | 2017-08-09 | 2024-07-18 | 사노피 | 지방간 질환 및 지방간염의 치료에서의 glp-1/글루카곤 수용체 작용제 |
| US11236142B2 (en) * | 2017-08-16 | 2022-02-01 | Dong-A St Co., Ltd. | Acylated oxyntomodulin peptide analog |
| EP3708577B1 (en) * | 2017-11-06 | 2024-09-04 | Shenzhen Turier Biotech Co., Ltd. | Treatment of biliary cirrhosis based on oxyntomodulin analogue glp-1r/gcgr dual-target agonist peptide |
| WO2019171352A2 (en) * | 2018-03-08 | 2019-09-12 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| KR20200135618A (ko) * | 2019-05-23 | 2020-12-03 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물 |
| EP3823659A4 (en) * | 2018-07-19 | 2022-06-22 | D&D Pharmatech Inc. | PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE |
| WO2020017919A1 (ko) * | 2018-07-19 | 2020-01-23 | 한미정밀화학주식회사 | 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법 |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| WO2020128967A2 (en) * | 2018-12-19 | 2020-06-25 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| EP3939990A4 (en) * | 2019-02-15 | 2023-05-24 | Hanmi Fine Chemical Co., Ltd. | NOVEL INTERMEDIATE FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND PROCESS FOR THE PRODUCTION THEREOF |
| GB202001024D0 (en) * | 2020-01-24 | 2020-03-11 | Key Bioscience Ag | Oxyntomodulin mimetics |
| KR20220050820A (ko) * | 2020-10-16 | 2022-04-25 | 한미약품 주식회사 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| EP1060746A4 (en) | 1998-03-06 | 2002-06-19 | Chugai Pharmaceutical Co Ltd | PROTEIN-FREE PREPARATIONS |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7217845B2 (en) | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005035761A1 (en) | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
| US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| US20090238838A1 (en) | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| BRPI0406606A (pt) | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| CA2589800A1 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| WO2006086769A2 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| WO2006134340A2 (en) * | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| GB0511986D0 (en) | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| AU2007221366B2 (en) * | 2006-02-22 | 2012-08-23 | Msd Italia S.R.L. | Oxyntomodulin derivatives |
| EP2046367A4 (en) | 2006-06-07 | 2009-11-11 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| GB0624868D0 (en) | 2006-12-13 | 2007-01-24 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EA017849B1 (ru) | 2007-02-15 | 2013-03-29 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соагонисты глюкагоновых/glp-1-рецепторов |
| EA201070121A1 (ru) | 2007-07-10 | 2010-06-30 | Эли Лилли Энд Компани | Лекарственная форма, содержащая слитый белок glp-1-fc |
| WO2009040068A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2009058734A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| PA8830501A1 (es) | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| WO2010013012A2 (en) | 2008-08-01 | 2010-02-04 | Lund University Bioscience Ab | Novel polypeptides and uses thereof |
| MX2011003117A (es) | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
| WO2010033220A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| ES2439499T3 (es) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
| US8680049B2 (en) * | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
| CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| CA2755133A1 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Selective and potent peptide inhibitors of kv1.3 |
| AU2010225523B2 (en) * | 2009-03-20 | 2012-05-24 | Hanmi Science Co., Ltd. | Method for preparing a site-specific physiologically active polypeptide conjugate |
| CN102459325B (zh) | 2009-06-16 | 2015-03-25 | 印第安纳大学科技研究有限公司 | 胃抑胜肽受体活化的胰高血糖素化合物 |
| PT2454282E (pt) | 2009-07-13 | 2015-06-23 | Zealand Pharma As | Análogos de glucagão acilados |
| US20120294855A1 (en) | 2009-11-03 | 2012-11-22 | Eli Lilly & Company | Glp-1 receptor agonist compounds for obstructive sleep apnea |
| US20120269830A1 (en) * | 2009-12-07 | 2012-10-25 | Lawrence Horowitz | Conjugates with improved pharmacokinetic properties |
| US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| AR079345A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| BR112012024379A2 (pt) | 2010-03-26 | 2017-01-10 | Novo Nordisk As | "peptídeos glucagon, seu uso, bem como composição farmacêutica" |
| CN103179976A (zh) * | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CN101974077A (zh) * | 2010-09-15 | 2011-02-16 | 南京瑞年天平医药科技有限公司 | 一种新颖的多肽化合物 |
| KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| KR101767570B1 (ko) * | 2010-10-26 | 2017-08-14 | 한미사이언스 주식회사 | 항 비만 펩타이드의 지속형 결합체 |
| CN102010473A (zh) | 2010-11-10 | 2011-04-13 | 曹鹏 | 重组胃泌酸调节素融合蛋白及其制备和应用 |
| AR084558A1 (es) | 2010-12-22 | 2013-05-22 | Marcadia Biotech | Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1) |
| EP2492749A1 (en) | 2011-02-28 | 2012-08-29 | Rohm and Haas Electronic Materials LLC | Photoresist compositions and methods of forming photolithographic patterns |
| KR101161526B1 (ko) | 2011-05-16 | 2012-07-02 | 숭실대학교산학협력단 | 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법 |
| RU2739209C2 (ru) | 2011-06-10 | 2020-12-21 | Ханми Сайенс Ко., Лтд. | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения |
| SI2721062T1 (sl) * | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
| CA2839867A1 (en) | 2011-06-22 | 2012-12-27 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| KR101665009B1 (ko) | 2012-03-09 | 2016-10-11 | 한미사이언스 주식회사 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
| WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
| JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| US9724420B2 (en) * | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| JP6137046B2 (ja) | 2014-05-09 | 2017-05-31 | 信越化学工業株式会社 | 単量体、高分子化合物、レジスト材料及びパターン形成方法 |
-
2012
- 2012-07-25 KR KR1020120081475A patent/KR101968344B1/ko active Active
-
2013
- 2013-07-24 AR ARP130102654A patent/AR091903A1/es not_active Application Discontinuation
- 2013-07-25 US US14/415,200 patent/US20150182593A1/en not_active Abandoned
- 2013-07-25 SG SG11201500519UA patent/SG11201500519UA/en unknown
- 2013-07-25 CN CN201380039596.XA patent/CN104507492B/zh active Active
- 2013-07-25 EP EP13823727.6A patent/EP2884994B1/en active Active
- 2013-07-25 DK DK18169490.2T patent/DK3384925T3/da active
- 2013-07-25 UA UAA201501078A patent/UA118177C2/uk unknown
- 2013-07-25 CN CN201710990018.4A patent/CN107854691B/zh active Active
- 2013-07-25 NZ NZ731657A patent/NZ731657A/en unknown
- 2013-07-25 EP EP20188520.9A patent/EP3766520A1/en active Pending
- 2013-07-25 TW TW102126623A patent/TWI661837B/zh active
- 2013-07-25 RU RU2017143004A patent/RU2768853C1/ru active
- 2013-07-25 PE PE2015000094A patent/PE20150633A1/es not_active Application Discontinuation
- 2013-07-25 EP EP18169490.2A patent/EP3384925B1/en active Active
- 2013-07-25 BR BR122022025353-9A patent/BR122022025353B1/pt active IP Right Grant
- 2013-07-25 CA CA2888407A patent/CA2888407C/en active Active
- 2013-07-25 JP JP2015524182A patent/JP2015524427A/ja active Pending
- 2013-07-25 ES ES13823727T patent/ES2942187T3/es active Active
- 2013-07-25 TW TW106127084A patent/TWI708614B/zh active
- 2013-07-25 MY MYPI2015000190A patent/MY171493A/en unknown
- 2013-07-25 MX MX2015001218A patent/MX360024B/es active IP Right Grant
- 2013-07-25 NZ NZ705384A patent/NZ705384A/en unknown
- 2013-07-25 SG SG10201700527UA patent/SG10201700527UA/en unknown
- 2013-07-25 CA CA3121985A patent/CA3121985A1/en active Pending
- 2013-07-25 BR BR112015001596-4A patent/BR112015001596B1/pt active IP Right Grant
- 2013-07-25 UA UAA201807966A patent/UA128812C2/uk unknown
- 2013-07-25 RU RU2015104492A patent/RU2642267C2/ru active
- 2013-07-25 WO PCT/KR2013/006668 patent/WO2014017843A1/en not_active Ceased
- 2013-07-25 TW TW109133876A patent/TWI780493B/zh active
- 2013-07-25 AU AU2013293714A patent/AU2013293714B2/en active Active
- 2013-07-25 ES ES18169490T patent/ES2842881T3/es active Active
-
2015
- 2015-01-23 PH PH12015500158A patent/PH12015500158B1/en unknown
- 2015-01-23 CL CL2015000177A patent/CL2015000177A1/es unknown
- 2015-01-25 IL IL236913A patent/IL236913B/en active IP Right Grant
- 2015-01-26 MX MX2018012686A patent/MX2018012686A/es unknown
- 2015-02-24 ZA ZA2015/01238A patent/ZA201501238B/en unknown
-
2016
- 2016-03-31 US US15/086,499 patent/US9901621B2/en active Active
-
2017
- 2017-09-27 CL CL2017002432A patent/CL2017002432A1/es unknown
- 2017-12-19 US US15/846,395 patent/US10493132B2/en active Active
-
2018
- 2018-01-19 JP JP2018007302A patent/JP6499333B2/ja active Active
- 2018-05-28 AU AU2018203729A patent/AU2018203729B2/en active Active
- 2018-12-24 MY MYPI2018002701A patent/MY187988A/en unknown
-
2019
- 2019-03-14 JP JP2019046854A patent/JP6903086B2/ja active Active
- 2019-04-23 CL CL2019001115A patent/CL2019001115A1/es unknown
- 2019-05-21 PH PH12019501131A patent/PH12019501131A1/en unknown
- 2019-08-13 ZA ZA2019/05331A patent/ZA201905331B/en unknown
-
2020
- 2020-04-21 IL IL274106A patent/IL274106B2/en unknown
- 2020-09-01 CL CL2020002262A patent/CL2020002262A1/es unknown
-
2021
- 2021-04-02 JP JP2021063405A patent/JP2021107403A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11197914B2 (en) | 2016-04-22 | 2021-12-14 | Shenzhen Turier Biotech Co. Ltd. | GLP-1R/GCGR dual target agonist polypeptide for treatment of fatty liver diseases, hyperlipemia and arteriosclerosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524427A5 (enExample) | ||
| JP2015536943A5 (enExample) | ||
| IL274106B2 (en) | The composition containing an oxyntomodulin derivative for the treatment of hyperlipidemia | |
| JP2017529354A5 (enExample) | ||
| van der Most et al. | Statins: mechanisms of neuroprotection | |
| Colonna et al. | Beyond apoptosis in lupus | |
| JP2011528333A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| WO2012011752A3 (en) | Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity | |
| WO2013009545A8 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| JP2014501762A5 (enExample) | ||
| JP2007500236A5 (enExample) | ||
| WO2011127304A3 (en) | Methods of treating an overweight subject | |
| JP2019530713A5 (enExample) | ||
| JP2010533705A5 (enExample) | ||
| Freyne | A case report of immunosuppressant medication‒associated polyarticular tophaceous gout successfully treated using the polyethylene glycol‒conjugated uricase enzyme pegloticase | |
| JP2007533733A5 (enExample) | ||
| WO2013036309A3 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| JP2016508506A5 (enExample) | ||
| JP2014510741A5 (enExample) | ||
| UA111415C2 (uk) | Фармацевтичний препарат, що містить похідну дигідрохіназоліну з противірусною активністю | |
| JP7729783B2 (ja) | ペグ化ウリカーゼの処方物および用量 | |
| JP2014505107A5 (enExample) | ||
| BR112013030067A2 (pt) | "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo" | |
| Shelton et al. | Subcutaneous DMPA: a better lower dose approach |